Alira Health Acquires RedCrow, an Equity Crowdfunding Platform for Healthcare Startups
11.5.2022 16:00:00 EEST | Business Wire | Press release
Alira Health (www.alirahealth.com), a global healthcare advisory and technology company, today announced the acquisition of RedCrow, an alternative investment platform that provides individual investors with easy access to expert-vetted healthcare start-ups. The financial terms of the transaction were not disclosed.
RedCrow was launched in 2016 by Brian Smith, a former Morgan Stanley financial advisor, and Jerry Harrison, an entrepreneur and member of the Rock and Roll Hall of Fame with Talking Heads. RedCrow mines the “wisdom of the crowd” to help find companies that resonate with an audience that may not only use a product but also invest in and realize a return from the company that invented it. This acquisition extends Alira Health’s ability to partner with patients across the lifecycle of drug and device development into the financing phase for early-stage pharma, MedTech, and healthcare services solutions.
“From personal experience, the founders at RedCrow recognize that not every drug or device receives the right investment,” said Gabriele Brambilla, CEO, and founder of Alira Health. “By reinventing and democratizing the way early-stage companies get funded, RedCrow helps more healthcare solutions come to market that can save patients’ lives. Alira Health already partners with patients across the development lifecycle. With RedCrow, we can now involve patients, their care circles, and other investors in the financing phase for new products that may also improve their care outcomes.”
RedCrow’s Brian Smith added, “We founded RedCrow with the belief that healthcare investing should be more immediate, transparent, and accessible, and that patients and their family members should be able to help fund future developments that may impact their own care. We embrace Alira Health’s mission to humanize healthcare and view our platform as a natural extension of Alira Health’s business model. At the same time, early-stage companies on the RedCrow platform can benefit from the breadth of Alira Health’s extensive services offering.”
Since its founding, RedCrow has marketed over 250 fundraises totaling $250 million. Recent success stories include HeartBeam (NASDAQ: BEAT), Sen Jam Pharmaceutical, Activ Surgical and Centerline Biomedical.
About RedCrow
Headquartered in Mill Valley, Calif., RedCrow, which was created because of the 2012 Jobs Act, is a direct investment and marketing platform for healthcare innovation, providing curated deal flow for all investors. RedCrow leverages both the industry experts to provide comprehensive analysis on healthcare startups, enabling a wide array of investors to help healthcare innovation succeed. When a startup joins RedCrow, it's equipped with the tools it needs, like virtual deal rooms, to market its company and investment opportunity. RedCrow leverages the knowledge of its advisory board, which includes financial, scientific, and medical professionals, along with its online community of investors, healthcare professionals, and patients to identify and support innovative companies.
Learn more at https://www.redcrow.com/home/what-we-do.html. Follow RedCrow on Twitter (@RedCrowCrowd) at https://twitter.com/RedCrowCrowd and LinkedIn at https://www.linkedin.com/company/redcrow-crowd/.
About Alira Health
Alira Health is an international patient-centric and technology-enabled advisory firm whose mission is to humanize healthcare. We work with healthcare and life sciences organizations looking for support across their entire solutions lifecycle. From development to medical care, we complement our clients’ expertise with a full spectrum of services including research and clinical development solutions, technology-powered consulting, and real-world evidence.
Our integrated and multidisciplinary team of over 500 scientists, strategists, economists, clinicians, and biostatisticians collaborate across our North American, European, and Asian offices and advise 80% of the top 50% of MedTech companies and 75% of the top 50% of Pharma companies.
Learn more at https://alirahealth.com/. Follow Alira Health on Twitter (@AliraHealth) at https://twitter.com/alirahealth and LinkedIn at https://www.linkedin.com/company/alira-health/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220511005026/en/
Contact information
Corporate
Susan Irving
Vice President of Global Marketing
susan.irving@alirahealth.com
Media
David Schull
President, Russo Partners LLC
david.schull@russopartnersllc.com
Olipriya Das
Senior Account Executive, Russo Partners LLC
olipriya.das@russopartnersllc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hologic Signs Definitive Agreement to Acquire Reveal Genomics19.10.2026 22:30:00 EEST | Press release
Hologic, a global leader in women’s health, today announced that it has signed a definitive agreement to acquire Reveal Genomics, a precision oncology company based in Barcelona, Spain, that develops advanced genomic diagnostic tests to help personalized cancer treatment, including its HER2DX test to help optimize therapy for patients with HER2-positive breast cancer. Breast cancer remains one of the most significant health challenges women face today. Reveal Genomics’ tests are highly complementary to Hologic’s existing oncology diagnostics, including the Breast Cancer Index® (BCI) test, the guideline-recognized genomic assay to help inform decisions regarding extended endocrine therapy in women with HR+ early-stage breast cancer. The combination of Hologic’s existing testing with Reveal Genomics’ portfolio represents a significant expansion of Hologic’s diagnostic oncology solutions, with the combined offering of new and existing testing expected to help inform treatment decisions fo
An Active Role in Freshness: ProAmpac Introduces ProActive Intelligence Shelf Protect19.10.2026 22:27:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, introduces ProActive Intelligence™ Shelf Protect (SP) Series, giving food producers a new way to help preserve product quality and reduce costly spoilage. Designed for select meat, seafood, and dairy applications, the technology is FDA- and USDA-compliant for intended uses in fresh beef, fresh pork, cooked sausage, deli meat, fresh salmon, and fresh cheese. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019305953/en/ Clearshield®-SP Shrink Bag This direct food-contact biotechnology packaging helps reduce microbial growth associated with food spoilage in intended applications, supporting longer shelf life throughout storage and distribution. Shelf Protect’s patented biotechnology is built directly into food-contact packaging film. “For meat processors, every product lost represents an investment in production, packaging, and distribution that goes unreal
Vedanta Ltd Doubles Zinc Capacity in South Africa with US$ 600 Mn investment19.10.2026 20:19:00 EEST | Press release
Vedanta Limited doubled its annual zinc production capacity to 500,000 tonnes1in South Africa through an investment of nearly US$ 600 Mn at Gamsberg (Phase II) at Vedanta Zinc International (VZI). Gamsberg has one of the world’s most significant zinc deposits and is VZI’s flagship zinc mine. Inaugurated by South African President Cyril Ramaphosa and Vedanta Limited Director Priya Agarwal-Hebbar, this expansion marks one of the decade’s largest mining investments in South Africa. It advances Vedanta Limited’s position as the world’s largest2 zinc producer, with a vision of achieving 3 million tonnes of annual production across India and South Africa. Of this, 2 million tonnes are targeted from its subsidiary, Hindustan Zinc Limited the world’s largest integrated zinc producer, while Vedanta Zinc International business aims to contribute 1 million tonnes annually. This expansion strengthens the ZAR 21 Bn (nearly US$ 1.5 Bn) investment commitment Vedanta made at the 2018 South Africa Inve
Unlocking Digital Gold’s US$700bn Opportunity19.10.2026 19:00:00 EEST | Press release
The digital gold market, worth US$45–55bn today, could unlock up to US$700bn in latent demand, according to new research from World Gold Council and Boston Consulting Group. The report points to substantial untapped appetite among retail investors, with nearly nine in ten surveyed saying they would consider digital gold under the right conditions. The US$700bn opportunity represents the report’s estimate of total latent demand that could be released if today’s barriers to adoption were removed, rather than a near-term forecast. The report’s five-year base case sees digital gold growing by around 27% a year to US$160–170bn by 2031. That could rise to US$270–280bn over the same time if more barriers fall faster. Momentum is already building as financial markets undergo a broader digital transformation, bringing tokenised investment products increasingly into the mainstream. Tokenised gold, one segment of the digital gold market alongside vaulted digital gold, has grown fivefold in value
Roquette Brings Broad Portfolio of Excipient Solutions and Technical Expertise to AAPS PharmSci 360 202619.10.2026 17:00:00 EEST | Press release
Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, will showcase its expansive portfolio of excipients, capsules, coatings, and biopharma solutions at AAPS PharmSci 360 2026. The conference and trade show will take place October 26-28 in New Orleans, Louisiana, USA. At Booth 1100 in the exhibit hall, Roquette’s Health & Pharma Solutions team will share their expertise across controlled-release technologies, hydroxypropyl beta-cyclodextrins, and sustainable formulation approaches, alongside a comprehensive portfolio of innovative solutions designed to address the evolving needs of pharmaceutical developers. “AAPS PharmSci 360 is a key opportunity to share our latest innovations, as well as highlight the breadth and depth of our scientific know-how that helps our customers solve complex formulation challenges,” said Peter Freed, Head of Technical Service & Development North America for Roquette’s Health & Pharma Solutions Business Unit. “From a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom